Changing trends in the management of chronic granulocytic leukemia

Research output: Contribution to journalArticle

Abstract

Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.

Original languageEnglish (US)
Pages (from-to)163-166
Number of pages4
JournalInternational Journal of Oncology
Volume6
Issue number1
StatePublished - 1995

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Disease Management
Cytogenetics
Disease Progression
Chromosomes

Keywords

  • bone marrow transplantation
  • cytogenetic remissions
  • interferon therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Changing trends in the management of chronic granulocytic leukemia. / Tefferi, Ayalew.

In: International Journal of Oncology, Vol. 6, No. 1, 1995, p. 163-166.

Research output: Contribution to journalArticle

@article{ccc69a67cc694a598e0bea51838f3061,
title = "Changing trends in the management of chronic granulocytic leukemia",
abstract = "Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.",
keywords = "bone marrow transplantation, cytogenetic remissions, interferon therapy",
author = "Ayalew Tefferi",
year = "1995",
language = "English (US)",
volume = "6",
pages = "163--166",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Changing trends in the management of chronic granulocytic leukemia

AU - Tefferi, Ayalew

PY - 1995

Y1 - 1995

N2 - Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.

AB - Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.

KW - bone marrow transplantation

KW - cytogenetic remissions

KW - interferon therapy

UR - http://www.scopus.com/inward/record.url?scp=0028950027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028950027&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 163

EP - 166

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -